Atossa Genetics completes all dosing and clinical visits in its phase 1 study
Atossa announced it has completed dosing and clinical visits in its Phase 1 study of its proprietary topical Endoxifen in men. The objectives of the placebo-controlled, repeat dose study are to assess the pharmacokinetics of a proprietary topical Endoxifen dosage form over 28 days. June 20, 2018